University of Colorado Anschutz Medical Campus/University of Colorado Denver
Welcome,         Profile    Billing    Logout  
 3 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Corboy, John
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
RISEMS, NCT03586986: Risk Factors in Early Multiple Sclerosis

Recruiting
N/A
300
US
Brain MRI, Blood analysis, Bioscreen, Symbol Digit Modality Test (SDMT)
University of Colorado, Denver, Colorado School of Public Health
Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers, Clinically Isolated Syndrome, Radiologically Isolated Syndrome
05/24
05/24
Vollmer, Timothy
NCT04650321: Home Based Infusions for Ocrelizumab

Recruiting
4
110
US
Ocrelizumab at home
University of Colorado, Denver, Genentech, Inc.
Multiple Sclerosis
08/21
08/21
Hebert, Jeffrey
No trials found
Weitzenkamp, David
No trials found

Download Options